EUVIMEDEUVIMED entdecken
Crossref

Efficacy and Tolerability of Lacosamide in Pediatric and Young Adult Epilepsy Patients with Severe Motor and Intellectual Disabilities

Nobutsune Ishikawa iD, Shin Suzuki, Ryota Komori, Hiroki Izumo iD, Satoshi Goda, Ayana Tsuboi, Kazuhiko Jinno

Neuropediatrics · 01.04.2025 · 56 (02) · 119-124

DOI: 10.1055/a-2508-5990 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuropediatrics, erschienen am 01.04.2025. Verfasst von Nobutsune Ishikawa und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Hiroshima Prefectural Hospital, Minami-ku, Hiroshima, Japan. Hauptthemen laut MEDLINE: Lacosamide, Anticonvulsants, Intellectual Disability, Drug Resistant Epilepsy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Epilepsy is common among patients with severe motor and intellectual disabilities (SMID) patients, often taking a prolonged and intractable course. Lacosamide (LCM) is widely used to treat epilepsy in both adults and children. We assess the efficacy and tolerability of LCM among pediatric and young adult epilepsy patients with SMID who suffer from intractable seizures.

Methods

This retrospective analysis reviewed the medical records of SMID patients undergoing LCM treatment for more than a year. The study included 24 patients (14 males) aged 3 to 29 years. Epilepsy was classified as focal in 17 patients, generalized in 4 patients, and combined generalized and focal in 3 patients.

Results

The retention rates were 70.8%, 65%, and 52.9% at 1, 2, and 3 years after LCM initiation, respectively. The 50% responder rate (achieving >50% seizure reduction) for LCM treatment was 50%, with two patients experiencing complete seizure control (absence of seizures for 6 months before the follow-up visit). The 50% responders included a higher proportion of patients with focal epilepsy (58.8%) compared to those with generalized epilepsy (25.0%). Treatment-emergent adverse events (TEAEs) included somnolence in five patients and nausea in two patients. TEAEs, particularly nausea, developed within 1 month after treatment initiation in two patients, leading to LCM discontinuation.

Conclusion

LCM demonstrated good efficacy for intractable epilepsy in pediatric and young adult SMID patients. It was generally well-tolerated, resulting in a favorable retention rate. LCM emerged as a useful antiseizure medication for epilepsy treatment in pediatric and young adult SMID patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LacosamideAnticonvulsantsIntellectual DisabilityDrug Resistant EpilepsyEpilepsyMotor DisordersHumansMaleFemaleAdolescentChildYoung AdultRetrospective StudiesChild, PreschoolAdultTreatment Outcome

Substanzen

LacosamideAnticonvulsants

Autor:innen und Institutionen

  • Department of Pediatrics, Hiroshima Prefectural Hospital, Minami-ku, Hiroshima, Japan.

ORCID-Profile: Nobutsune Ishikawa, Hiroki Izumo

Zitieren

APA

Ishikawa, N., Suzuki, S., Komori, R., Izumo, H., Goda, S., Tsuboi, A., & Jinno, K. (2025). Efficacy and Tolerability of Lacosamide in Pediatric and Young Adult Epilepsy Patients with Severe Motor and Intellectual Disabilities. Neuropediatrics, 56(02), 119-124. https://doi.org/10.1055/a-2508-5990

Vancouver

Ishikawa N, Suzuki S, Komori R, Izumo H, Goda S, Tsuboi A, et al. Efficacy and Tolerability of Lacosamide in Pediatric and Young Adult Epilepsy Patients with Severe Motor and Intellectual Disabilities. Neuropediatrics. 2025;56(02):119-124. doi:10.1055/a-2508-5990

BibTeX
@article{Ishikawa2025,
  author = {Ishikawa, Nobutsune and Suzuki, Shin and Komori, Ryota and Izumo, Hiroki and Goda, Satoshi and Tsuboi, Ayana and Jinno, Kazuhiko},
  title = {Efficacy and Tolerability of Lacosamide in Pediatric and Young Adult Epilepsy Patients with Severe Motor and Intellectual Disabilities},
  journal = {Neuropediatrics},
  year = {2025},
  volume = {56},
  number = {02},
  pages = {119--124},
  doi = {10.1055/a-2508-5990}
}
Kostenlos starten →